Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner

Miao Zeng,Wei Zhang,Yisheng Li,Li Yu

DOI: https://doi.org/10.1186/s40364-024-00581-1

2024-03-25

Biomarker Research

Abstract:Abstract Recombinant adenovirus (rAd) regimens, including replication-competent oncolytic adenovirus (OAV) and replication-deficient adenovirus, have been identified as potential cancer therapeutics. OAV presents advantages such as selective replication, oncolytic efficacy, and tumor microenvironment (TME) remodeling. In this perspective, the principles and advancements in developing OAV toolkits are reviewed. The burgeoning rAd may dictate efficacy of conventional cancer therapies as well as cancer immunotherapies, including cancer vaccines, synergy with adoptive cell therapy (ACT), and TME reshaping. Concurrently, we explored the potential of rAd hitchhiking to adoptive immune cells or stem cells, highlighting how this approach facilitates synergistic interactions between rAd and cellular therapeutics at tumor sites. Results from preclinical and clinical trials in which immune and stem cells were infected with rAd have been used to address significant oncological challenges, such as postsurgical residual tumor tissue and metastatic tissue. Briefly, rAd can eradicate tumors through various mechanisms, resulting from tumor immunogenicity, reprogramming of the TME, enhancement of cellular immunity, and effective tumor targeting. In this context, we argue that rAd holds immense potential for enhancing cellular immunity and synergistically improving antitumor effects in combination with novel cancer immunotherapies.

oncology,medicine, research & experimental

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore how to utilize the application of recombinant adenovirus (rAd) in cancer immunotherapy, especially to improve the anti - cancer effect by stimulating cellular immunity and specific cell - targeted delivery. Specifically, the paper focuses on:

1. **The potential of recombinant adenovirus (rAd) in cancer immunotherapy**: The paper discusses the advantages of rAd as a potential cancer treatment method, especially its role in tumor immunogenicity, tumor microenvironment (TME) remodeling, enhancing cellular immunity, and effective tumor targeting.

2. **The development and application of conditionally replicating adenovirus (CRAd) or oncolytic adenovirus (OAV)**: OAV is designed to be able to selectively replicate in tumor cells, thereby killing tumor cells and being able to remodel the tumor microenvironment and enhance the immune response. The paper reviews the development principles of OAV and the progress of its application in cancer treatment.

3. **The synergy between rAd and cell therapies (such as adoptive cell therapy ACT)**: The paper explores how rAd can be used in combination with different types of immune cells (such as dendritic cells, CAR - T cells, etc.) to enhance the effect of immunotherapy. In particular, the paper mentions that rAd improves the treatment effect through the "viral hitchhiking" phenomenon, that is, being loaded on the cell surface or infecting cells, and causing an oncolytic effect after reaching the tumor site.

4. **The delivery strategies of rAd**: The paper discusses different delivery methods of rAd, including intravenous injection and local injection, and the application of these methods in pre - clinical and clinical trials. In addition, it also introduces how to genetically engineer rAd to improve its ability to enter cells and its specificity.

In summary, this paper aims to comprehensively overview the application potential of recombinant adenovirus in cancer immunotherapy and how to further enhance its treatment effect through technological improvement and combination with other treatment methods.